Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update
03 mai 2021 08h00 HE
|
Vaxart, Inc.
Vaxart to advance three oral tablet COVID-19 vaccine candidates to the clinic: VXA-CoV2-1 (includes both the S and the N proteins) into Phase II and two S-only constructs into Phase I/IIFour clinical...
Vaxart to Present at the World Vaccine Congress Washington 2021
29 avr. 2021 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by...
Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines
26 avr. 2021 08h00 HE
|
Vaxart, Inc.
Vaxart to provide new data from its Phase I COVID-19 trial Stanford University T-cell expert to discuss cross-protection against variants SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE...
Vaxart Appoints David Wheadon, M.D., to its Board of Directors
23 avr. 2021 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by...
Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans
22 avr. 2021 08h00 HE
|
Vaxart, Inc.
Nearly 19 million Americans who will decline vaccines would get vaccinated if they had a pill option, Vaxart’s poll finds Seven in 10 said they would prefer a pill over an injection SOUTH SAN...
Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference
04 mars 2021 16h01 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by...
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
25 févr. 2021 16h01 HE
|
Vaxart, Inc.
VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021Cash and cash equivalents of $126.9 million as of December 31,...
Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021
24 févr. 2021 16h01 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than...
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
03 févr. 2021 08h30 HE
|
Vaxart, Inc.
Study reached primary and secondary endpoints of safety and immunogenicity, respectivelyVXA-CoV2-1 induced potent CD8+ T-cell responsesVXA-CoV2-1 potentially protective against new and emerging...
Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine
27 janv. 2021 08h30 HE
|
Vaxart, Inc.
A computational simulation model showed that a norovirus vaccine costing as much as $1,300 can still be cost saving in children under 5 The model also showed a norovirus vaccine costing $100 can be...